Claims for Patent: 10,617,760
✉ Email this page to a colleague
Summary for Patent: 10,617,760
| Title: | Composition for target-specific photothermal therapy |
| Abstract: | Provided are a composition for target-specific photothermal therapy and a method of photothermal therapy using the composition and more particularly, a method of photothermal therapy for selectively killing inflammatory cells by using the composition for target-specific photothermal therapy comprising carbon nanotubes coated with dextran.According to the present invention, the composition for photothermal therapy comprising the carbon nanotubes coated with dextran is absorbed only into desired target cells, i.e., inflammatory cells, and causes thermotherapeutic action through light irradiated from an external light source, while not damaging cells except for inflammatory cells. The method of photothermal therapy using the composition for photothermal therapy has advantages of minimizing side effects and maximizing therapeutic effects. |
| Inventor(s): | Woo Jae Kim, Jo-Eun UM |
| Assignee: | Industry Academic Cooperation Foundation of Gachon University |
| Application Number: | US15/558,308 |
Details for Patent 10,617,760
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | STRENSIQ | asfotase alfa | Injection | 125513 | October 23, 2015 | ⤷ Start Trial | 2036-02-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,617,760
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016148402 | ⤷ Start Trial |
| United States of America | 2018133317 | ⤷ Start Trial |
| South Korea | 101556144 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
